About

Anna Sipitanou holds a BSc in Chemistry and an MSc in Drug Discovery & Pharmaceutical Sciences. She was Head of Business Development at Copley Scientific until August 2022, after which she moved to Recipharm.

Having worked closely with pharmaceutical companies on a wide range of OINDP projects, Ms Sipitanou has gained specialist knowledge of the regulatory requirements for both delivered dose uniformity and aerodynamic particle size distribution testing, as well as extensive experience in methods to improve in vitro–in vivo correlations (IVIVC) and other specialist testing applications, including generic drug development, inhaled dissolution and facemask testing.

Contributions

NASAL

IMPROVING IN VITRO TEST METHODS FOR NASAL DRUG PRODUCTS

Mark Copley and Anna Sipitanou look at how in vitro testing is being refined for greater repeatability to maximise its value as a low-cost tool for product development, including an assessment of the role of automation in improving the sensitivity of in vitro testing.

More contributions

PULMONARY

SEMI-AUTOMATION IN INHALER TESTING – EXPLORING THE POTENTIAL AND PRACTICALITIES

João Pereira, Raquel Borda D’Água, Mark Copley and Anna Sipitanou, discuss the semi-automation of cascade impactor testing and the benefits it can bring in terms of quality of orally inhaled product test data, and reductions in cost and effort associated with routine, critical measurements.